Navigation Links
Therapeutic cloning treats Parkinson's disease in mice
Date:3/23/2008

NEW YORK, March 23, 2008Research led by investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) has shown that therapeutic cloning, also known as somatic-cell nuclear transfer (SCNT), can be used to treat Parkinsons disease in mice. The studys results are published in the March 23 online edition of the journal Nature Medicine.

For the first time, researchers showed that therapeutic cloning or SCNT has been successfully used to treat disease in the same subjects from whom the initial cells were derived. While this current work is in animals, it could have future implications as this method may be an effective way to reduce transplant rejection and enhance recovery in other diseases and in other organ systems.

In therapeutic cloning or SCNT, the nucleus of a somatic cell from a donor subject is inserted into an egg from which the nucleus has been removed. This cell then develops into a blastocyst from which embryonic stem cells can be harvested and differentiated for therapeutic purposes. As the genetic information in the resulting stem cells comes from the donor subject, therapeutic cloning or SCNT would yield subject-specific cells that are spared by the immune system after transplantation.

The new study shows that therapeutic cloning can treat Parkinsons disease in a mouse model. The scientists used skin cells from the tail of the animal to generate customized or autologous dopamine neuronsthe missing neurons in Parkinsons disease. The mice that received neurons derived from individually matched stem cell lines exhibited neurological improvement. But when these neurons were grafted into mice that did not genetically match the transplanted cells, the cells did not survive well and the mice did not recover.


'/>"/>

Contact: Jeanne D'Agostino
dagostij@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
2. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
3. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
4. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
5. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
6. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
7. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
8. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes
9. Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Childrens Hospital at Stanford
10. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
11. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 Demand Response ... with considerable benefits in reducing the imbalance between energy ... grid appliances have been rolled out (due to increasing ... Infrastructure (AMI). This helps in controlling residential appliances and ... growing in the North American region, and with government ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... 2014 With prom shopping reaching its ... retailer, is ready to showcase its new and trendy ... of evening dresses in its online shop. Additionally, it ... for these elegant gowns. According to the company’s sales ... July 26, 2014. , He says, “Now, worldwide ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... Va. (April 13, 2009) While the number of ... registry still only includes 38 percent of licensed drivers, according ... year. Yet, according to a new survey of Americans, ... even if their family disagrees. , "The number of ...
... Rx, Inc., the,pioneering force in measuring the impact of ... physicians, announces that Mark,Degatano has joined the company as ... a newly-created position that expands and,strengthens Impact Rx,s business ... his new role Degatano will lead programs at the ...
... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
... FARMINGDALE, N.Y., April 13 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has entered into a new, three year, ... Avanco Sistemas Medicos, based in Barcarena, Portugal, for the ...
... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
... As all eyes turn to the health reform debate in ... of California - will urge that "everything be on the ... D.C. Mr. Bodaken will participate in a keynote panel kicking ... that begins with an address by Dora Hughes, counselor to the ...
Cached Medicine News:Health News:While majority of Americans express interest in organ and tissue donation, few register 2Health News:Impact Rx, Inc. Names Mark Degatano as Vice President, Business Development, Key Client Initiatives 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)...   Ventana Medical Systems, Inc.  (Ventana), a member ... into an agreement with Merck KGaA, Darmstadt, ... the United States and ... biopharmaceutical division on the development and commercialization of a ... proprietary diagnostic assays. In alignment with Merck KGaA,s strategic ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Specialty Silicone Fabricators (SSF), a leading global ... inaugurated its state-of-the-art 102,000 square-foot facility today in ... facility joins all Paso Robles departments, operations and ... Tustin, Calif. and Elk Rapids, Mich. The new ...
... Ohio, May 29, 2012  Cardinal Health Specialty Solutions ... technology system that makes it easier for payors ... that improve the quality and cost of caring ... rheumatoid arthritis. One of Cardinal Health ...
Cached Medicine Technology:Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 3
... is a low profile implantable bipolar ... stimulation of either the atrium (preformed ... model). All ZY leads are supplied ... used to extend/retract the fixation helix ...
... are small profile endocardial permanent pacing leads ... lead body size of only 4.8 F ... F, the Physique lead is the smallest ... in both straight and pre-formed J configurations, ...
Used with Temporary Myocardial Heartwires....
Used with permanent pacing leads....
Medicine Products: